Additional Alemtuzumab Mechanism of Action Data Reported Genzyme Company reported four-year follow-up data from its completed Stage 2 multiple sclerosis trial showing around 71 % of alemtuzumab treated individuals remain free from clinically-active disease as much as 3 years after most sufferers received their last span of the investigational compound. The data were provided at the American Academy of Neurology annual getting together with prescription drugs . In the trial, alemtuzumab was presented with to patients in several annual cycles of only five days per cycle, while Rebif was given to patients three times per week, every whole week for three years. Outcomes of the four-year review found: an estimated 71 % of alemtuzumab-treated patients were free of clinically-active disease, compared to 35 % of patients taking Rebif (p..
Extra data from Auxilium XIAFLEX phase III studies on Peyronie’s disease Auxilium Pharmaceuticals, Inc. These data will be shown at the Sexual Medicines Society of North America /International Culture for Sexual Medicine Joint Annual Interacting with in Chicago, IL. A baseline analysis from IMPRESS focuses on the psychosocial impact on men with PD, particularly the amount of PD bother and distress associated with PD as related to the degree of penile curvature deformity. At baseline, results showed that all examples of curvature deformity evaluated in the studies may be associated with high degrees of bother and distress.